Previous 10 | Next 10 |
Strategic collaboration and licensing agreement further strengthens Galapagos’ growing early-stage pipeline in oncology precision medicine Collaboration leverages Galapagos’ expertise in small molecule drug discovery and development with BridGene’s innovative discover...
2024-01-02 12:32:09 ET More on COVID vaccine makers BioNTech's Strategic Shift: Diversifying Into Cancer Therapeutics Novavax: Do Not Expect A Turnaround In 2024 BioNTech's COVID-19 Success Paves The Way For A Strong Drug Pipeline Moderna upgraded at Oppenhei...
2024-01-02 02:37:43 ET More on Galapagos: Galapagos: Navigating Uncharted CAR-T Waters With A Cash Compass Galapagos concludes strategic evaluation and signs letter of intent to transfer Jyseleca business to Alfasigma For further details see: Galapagos to transfe...
Transaction expected to close in the first quarter of 2024, subject to customary closing conditions Michele Manto, Galapagos’ Chief Commercial Officer, to join Alfasigma Mechelen, Belgium; 02 January 2024, 07:00 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and Alfa...
Mechelen, Belgium; 19 December 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the first patient has been dosed in PAPILIO-1, the Phase 1/2 study to evaluate the safety, efficacy, and feasibility of our seven-day vein-to-vein, point-of-care manufactured BCMA CAR-T...
2023-12-13 11:51:32 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Galapagos (NASDAQ: GLPG ) just reported results for the third quarter of 2023. Galapagos reported earnings per share of 42 cents. This was above the analyst estimate for E...
2023-12-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Additional safety and efficacy data further support potential of innovative, decentralized approach to CAR-T manufacturing and transformational impact on patients with severe hematologic cancers Two poster presentations include recent data updates and additional data not included in the A...
Mechelen, Belgium; 6 December 2023, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will host a Key Opinion Leader (KOL) event during the 65th ASH Annual Meeting & Exposition in San Diego, CA, on Sunday, December 10, 2023, from 11:00 am PST to 12:30 pm PST. The i...
2023-11-21 11:00:00 ET Summary Galapagos pivots to CAR-T therapy, divesting Jyseleca; faces clinical, market risks amidst investor skepticism. Revenue up 9% YOY; operating losses reduced; strong cash reserve at $4.2B; net profit achieved. Negative enterprise value and underper...
News, Short Squeeze, Breakout and More Instantly...
Mechelen, Belgium; 16 May 2024, 22:01 CET; regulated information – Galapagos NV ((Euronext &, NASDAQ:GLPG) announced today that its Boar...
2024-05-11 10:14:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Advanced potentially best-in-class cell therapy and small molecule R&D pipeline comprising four clinical assets and >15 discovery programs...